[{"Assets_0_Q3_USD":1179935000.0,"CommonStockSharesOutstanding_0_Q3_shares":92080000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":49501000.0,"NetIncomeLoss_1_Q3_USD":53789000.0,"NetIncomeLoss_3_Q3_USD":3012000.0,"StockholdersEquity_0_Q3_USD":574515000.0,"EarningsPerShareBasic_1_Q3_USD":0.59,"EarningsPerShareBasic_3_Q3_USD":0.03,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":91859000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":91440000.0,"Ticker":"NBIX","CIK":"914475","name":"NEUROCRINE BIOSCIENCES INC","OfficialName":"Neurocrine Biosciences Inc. Common Stock","form":"10-Q","period":"20190930","fy":"2019.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"9338885763.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20191104"}]